Characteristics and responses of initial patients with measurable disease (n = 10)
| Patient . | Age/ sex . | Histology . | Prior therapies . | Sites of disease . | Total DCs given* . | Anti-Id responses . | Clinical response, time to progression . | Current status, subsequent therapies, months since DC vaccine . | |
|---|---|---|---|---|---|---|---|---|---|
| T cell . | Ab . | ||||||||
| D1† | 59/F | FM | Chl, ChlVB | Paracardiac, mediastinal | 69 × 106 | + | − | CR, 44 months | RD after CHOP, rituximab, XRT, fludarabine, repeat DC vaccine, 94 mos |
| D2† | 44/F | FM | Chl, CVP | Peri-aortic, para-iliac | 22 × 106 | + | − | PR, 12 months | NED after Id-KLH/SAF,1-153 fludarabine, 83 mos |
| D3† | 34/F | F/DSC | CVP, fludarabine | BM | 14 × 106 | + | +μ‡ | Cleared BM PCR signal | NED 79 mos after DC vaccine without subsequent therapies |
| D4† | 45/M | FSC | CVP, fludarabine | Cervical, axillary, peri-aortic, iliac, inguinal | 16 × 106 | + | − | PD at 10 mos | NED after MINE, rituximab, 69 mos |
| D5 | 50/F | FM | CVP, fludarabine | Peri-aortic, BM | 23 × 106 | + | − | PD at 7 mos | NED after Id-KLH/SAF,1-153 rituximab, 65 mos |
| D6 | 47/M | FSC | Chl, CHOP | Peri-aortic, spleen, mesenteric | 22 × 106 | + | − | PD at 12 mos | RD after Id-KLH/SAF,1-153 rituximab, XRT, 63 mos |
| D7 | 43/F | FSC | CHOP | Axillary, mesenteric | 27 × 106 | + | − | PD at 9 mos | MRD after rituximab, 58 mos |
| D8 | 40/M | FSC | CVP, XRT, CEP, fludarabine | Axillary, peri-aortic | 10 × 106 | + | +μ‡ | PD at 5 mos | NED after Id-KLH/SAF,1-153 57 mos |
| D9 | 43/F | FSC | Chl, Id-KLH/SAF | Axillary, iliac, peri-aortic | 13 × 106 | − | − | CR, 57 mos | PD at single site 57 mos after DC vaccine |
| D10 | 51/F | FM | CVP, fludarabine, CHOP | Axillary, spleen | 12 × 106 | − | − | PD at 7 mos | NED after Id-KLH/SAF,1-153 tositumomab, 47 mos |
| Patient . | Age/ sex . | Histology . | Prior therapies . | Sites of disease . | Total DCs given* . | Anti-Id responses . | Clinical response, time to progression . | Current status, subsequent therapies, months since DC vaccine . | |
|---|---|---|---|---|---|---|---|---|---|
| T cell . | Ab . | ||||||||
| D1† | 59/F | FM | Chl, ChlVB | Paracardiac, mediastinal | 69 × 106 | + | − | CR, 44 months | RD after CHOP, rituximab, XRT, fludarabine, repeat DC vaccine, 94 mos |
| D2† | 44/F | FM | Chl, CVP | Peri-aortic, para-iliac | 22 × 106 | + | − | PR, 12 months | NED after Id-KLH/SAF,1-153 fludarabine, 83 mos |
| D3† | 34/F | F/DSC | CVP, fludarabine | BM | 14 × 106 | + | +μ‡ | Cleared BM PCR signal | NED 79 mos after DC vaccine without subsequent therapies |
| D4† | 45/M | FSC | CVP, fludarabine | Cervical, axillary, peri-aortic, iliac, inguinal | 16 × 106 | + | − | PD at 10 mos | NED after MINE, rituximab, 69 mos |
| D5 | 50/F | FM | CVP, fludarabine | Peri-aortic, BM | 23 × 106 | + | − | PD at 7 mos | NED after Id-KLH/SAF,1-153 rituximab, 65 mos |
| D6 | 47/M | FSC | Chl, CHOP | Peri-aortic, spleen, mesenteric | 22 × 106 | + | − | PD at 12 mos | RD after Id-KLH/SAF,1-153 rituximab, XRT, 63 mos |
| D7 | 43/F | FSC | CHOP | Axillary, mesenteric | 27 × 106 | + | − | PD at 9 mos | MRD after rituximab, 58 mos |
| D8 | 40/M | FSC | CVP, XRT, CEP, fludarabine | Axillary, peri-aortic | 10 × 106 | + | +μ‡ | PD at 5 mos | NED after Id-KLH/SAF,1-153 57 mos |
| D9 | 43/F | FSC | Chl, Id-KLH/SAF | Axillary, iliac, peri-aortic | 13 × 106 | − | − | CR, 57 mos | PD at single site 57 mos after DC vaccine |
| D10 | 51/F | FM | CVP, fludarabine, CHOP | Axillary, spleen | 12 × 106 | − | − | PD at 7 mos | NED after Id-KLH/SAF,1-153 tositumomab, 47 mos |
FSC indicates follicular small cleaved cell; FM, follicular mixed small cleaved and large cell; F/DSC, follicular and diffuse small cleaved cell; Chl, chlorambucil; ChlVB, chlorambucil, vincristine, and bleomycin; CVP, cyclophosphamide, vincristine, and prednisone; CHOP, cyclophosphamide, adriamycin, vincristine, and prednisone; CEP, cyclophosphamide, etoposide, and prednisone; Id-KLH/SAF, Id protein coupled to KLH plus Syntex adjuvant formulation; XRT, radiation therapy; MINE, mesna, ifosfamide, mitoxantrone, etoposide; PD, progressive disease; NED, no clinical evidence of disease; MRD, minimum residual disease; RD, residual disease; Ab, antibody; BM, bone marrow.
Total number of DCs infused over the course of 4 vaccinations.
Previously reported in original pilot study.22
IgM, but not IgG anti-Id antibodies detectable in serum.
Revaccinated with Id-KLH plus SAF adjuvant. See Table 3.